Innate Immunotherapeutics Limited is a bio-technology company with offices in Australia and New Lealand. Since the companies announcement in May 2015 of joining a Unites States based consortium for multiple sclerosis (MS) the company has gained momentum in its clinical trails of its drug deemed MIS416. The medication’s target is secondary progressive multiple sclerosis (SPMS) to which currently no effective treatments exist.
Multiple sclerosis (MS) is a chronic autoimmune disorder affecting movement,sensations,bodily functions and more. It is caused by destruction of the myelin insulation covering nerve fibers (neurons) in the central nervous system (brain and spinal cord). When the myelin is destroyed, nerve messages are sent more slowly and less efficiently. Patches of scar tissue, called plaques or lesions form over the affected areas, further disrupting nerve communication. Symptoms of MS occur when the brain and spinal cord nerves no longer communicate properly with other parts of the body. MS causes a wide variety of symptoms and can affect vision, balance, strength, sensation, coordination, and bodily functions. MS rates are higher in the United States, Canada, and Northern Europe than inother parts of the world. Over 2.4 million people suffer from multiple sclerosis globally.
The companies embracing of the Multiple Sclerosis Outcome Consortium may help in getting the drug through process development faster since no effective medications exist for secondary progressive multiple sclerosis (SPMS).
Innate Immunotherapeutics MIS416 has successfully completed pre-clinical, Phase 1B and Phase 2A trials that examined the drug towards secondary progressive multiple sclerosis. The trials, along with a program run in New Zealand over the past six years have shown that MIS416 appears to be safe for usage at the dosages used in the initial trials and many patients have self-reported improvements as a result of trying MIS416. This clinical program has resulted in the companies research team understanding how MIS416 appears to be operating in patients who are afflicted with SPMS.
Currently there are no approved drugs available to provide safe, effective, long-term ongoing treatment for patients with SPMS.
The company is recruiting for a Phase 2B randomized, double-blind, placebo-controlled trial of the efficacy and safety of MIS416 in the treatment of subjects with Secondary Progressive Multiple Sclerosis (SPMS) is currently recruiting up to 90 patients in Australia and New Zealand (Wellington only). Patients with SPMS who might be interested in taking part in the trial should contact the company via this link: http://www.innateimmunotherapeutics.com/irm/content/clinical-trials.aspx?RID=307
Upon completion of the Phase 2B trials in 2016, Innate’s strategy is to license and sell to a large pharma company.
Innate Immunotherapeutics reported in July 2015 that it has claimed considerable success in attracting interest in the program from both pharmaceutical companies with existing drugs to treat relapsing-remitting MS as well as companies which have not previously been involved in the MS market.
This is simply fantastic news for people afflicted with secondary progressive multiple sclerosis (SPMS) as well as people with relapsing remitting multiple sclerosis (RRMS) since the natural course of RRMS is progressive to SPMS. The fact SPMS has not had as much focus placed upon it within the pharmaceutical community has been both troubling and worrisome to MS patients for many many years. We applaud Innate Immunotherapeutics for entering into this critical research and working rapidly to get this much needed medication to market along the most rapid means possible.
THANK YOU SO MUCH!
35 Lime Street
Phone +61 (0)2 8003 3650
New Zealand Office
4B Walls Road
Phone +64 (0)9 525 0532
Innate Immunotherapeutics Limited
PO Box 91806, Victoria Street West